Notice ID: 26e232b6ea474ecf94dff13a1ee96467Special Notice
Rapid COVID-19 Antigen Test Kits
Archived. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 3:00 PM UTC−05:00
- Posted
- December 22, 2021
- Notice type
- Special Notice
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of WarDepartment of the Army
Notice details
- Office
- W6QK ACC-APG NATICK
- Last updated
- Sep 25, 2026
Identifiers
- Solicitation number
- W58P0522R0003
- Notice ID
- 26e232b6ea474ecf94dff13a1ee96467
Description
Title: Request for Information (RFI) for COVID-19 Antigen Tests -- Over the Counter (OTC) Synopsis: NOTE: THIS IS A REQUEST FOR INFORMATION (RFI) The information requested in this announcement is being sought for informational planning purposes only and does not constitute a request for proposal, an announcement of a forthcoming solicitation or a commitment by the Government in any way. Also, it is not a request seeking contractors interested in being placed on a solicitation mailing list. All information is to be furnished at no cost or obligation to the Government, and is subject to change at any time. Response to this Request for Information is voluntary and no reimbursement will be made for any costs associated with providing information in response to this RFI. Data submitted in response to this Request for Information will not be returned. There is no solicitation available at this time. Description The United States Department of Defense (DoD) on behalf of the Department of Health and Human Services (HHS) is seeking information to assess market availability and sourcing of Federal Drug Administration (FDA) Emergency Use Authorization (EUA) or 510(k) cleared COVID-19 Antigen OTC test kits for personnel use. Questions: Respondents are requested to provide the following information: Company Name, mailing address, CAGE/SAM Code, website, point of contact, phone number, and email address. Business size under NAICS Code 325413 In-Vitro Diagnostic Substance Manufacturing Does your company currently have an approved Emergency Use Authorization (EUA) or 510(k) for the products? If not, has your company submitted a request to the FDA? When were the materials submitted? If the submission is an EUA, does the company have the ability to scale up manufacturing capacity to 500,000 or more tests per week within 3 months of authorization per FDA’s policy for prioritized review of EUA requests (https://www.fda.gov/media/135659/download)? 4. Does your company have manufacturing located within the United States to meet any requirements or would manufacturing outside the US be required? If outside the US, does your company currently export to the United States? Does your company ship directly or through a distributor? For a delivery location in California, USA, does your company anticipate utilizing air freight, ocean freight, or a combination? If a combination, please explain. 5. Does your company currently have fully manufactured, unallocated stock on hand that are available to ship within 2 weeks of a contract award? If so, how many tests are available? What is the approximate remaining shelf-life of the product? 6. What pack counts does your company currently offer in standard approved packaging? (ie. 1 test per pack, 2 tests per pack, ect.) What is the standard shipment count (ie. Pallet or shipper count(s))? 7. How much product, on a monthly basis, could the company produce for the months of January through April? 8. Provide any comments or questions on the associated draft Statement of Work. 9. If your company has previously provided similar items to the USG, please provide the name of the requiring activity and the contract number(s). Responses Due: Responses are due by 24 December 2021 Response Format: Responses are requested electronically by email to the following POCs: Brendon.m.courtade.civ@army.mil antoine.c.denson.civ@army.mil laurel.d.miller2.civ@army.mil Contracting Office Address: Army Contracting Command – Joint COVID-19 Response Division 6472 Integrity Court, Building 4401, ATTN: CCAP-CR Aberdeen Proving Ground, MD 21005-3013
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Brendon Courtade
Secondary Contact
Antoine Denson
Documents
No documents available.
Lifecycle
Solicitation:
W58P0522R0003- Special NoticeCurrentDec 22, 2021
Rapid COVID-19 Antigen Test Kits
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Procurement of rapid syndromic molecular testing reagents for the Seattle VA Medical Center. Please see Attachments for further information in regards to this acquisition. | 70% | Market Research | 08/06/2027 |
The VA Puget Sound Health Care System Pathology and Laboratory Medicine Service requires a histology staining workflow system which includes: Two (2) immunohistochemistry (IHC) and two (2) in-situ hybridization (ISH) immunostainers, and two (2) special stainers, and a specimen tracking system which promotes proper identification of specimens and slides and will audit workflow to identify areas that need improvement and reduce errors. The tracking system will improve patient safety, provide a chain of custody, and will monitor productivity. All the components of the workflow system must communicate with each other in order to track the workflow. The stainers attached to this system must be automated and allow the system to track and label slides for special staining and immunostaining. The workflow system must be compatible with the IT systems VISTA and/or Cerner, as well as any other new electronic health record system the VA acquires and also be compatible with Data Innovations middleware. | 68% | Market Research | 11/13/2026 |
This amendment incorporates GSAM Clause 552.238-120 Economic Price Adjustment – Federal Supply Schedule Contracts (Tailored) (Sep 2024), updates Responsibility Evaluation dated October 2025, and updates the Signature Authority form dated August 2025. | 63% | Solicitation | 03/17/2024 |
See Soliciation Amendments 0001, 0002, 0003, and 0004. USAISR's Combat Casualty Care Research Team 1 (CRT-1) requires resupply of its Blood Donor Room on a reoccurring basis in order to satisfy research requirements for blood collection. USAISR currently has three Terumo Trima Accel Blood Collection Systems in operation. These units support numerous research protocols. Various collection sets are used to collect a variety of blood products from donors. The Trima instrument is FDA-approved, but only with the use of original manufacturer-supplied consumable products. These consumables are specific to the instrument and there are no generic substitute products available in the marketplace. Please note - This is a 100% set-aside for Service-Disabled Veteran-Owned Small Businesses. See attached complete solicitation for all requirement details and instructions to offerors. | 59% | Solicitation | 12/02/2026 |
The purpose of this modification is to provide replacement supplies for discontinued items and provide increased quantity due to unanticipated increase in testing. The modification also incorporates FAR clause 52.40-91 Security Prohibitions and Exclusions based on FAR 40.205(b). | 59% | Special Notice | 11/18/2026 |
Additional Details
Solicitation Number
W58P0522R0003
Archive Date
Not specified
Office Address
ABERDEEN PROVING GROU, MD, 21005-0000